Amyl Therapeutics SRL
6.8 FTEAmyl Therapeutics reported total assets of €7.02m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jul 2026), with 6.8 full-time equivalents.
By total assets for 2025, Amyl Therapeutics ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Amyl Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -43 % Total assets +5 % Headcount (avg FTE) +196 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Amyl Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jul 2026
- Year ended 31 Dec 2024filed on 02 Jul 2025
- Year ended 31 Dec 2023filed on 05 Jun 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 29 Aug 2022
Amyl Therapeutics's financial analysis
- Solvency50.6%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Amyl Therapeutics
Amyl Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0758.775.372
- VAT number
- BE0758775372
- Peppol
- Registered · 0208:0758775372 · as of 12 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Nov 2020
- Registered office
- 4000 Liège
- Size
- Micro · 6.8 FTE
- Latest accounts
- 2025 · filed on 22 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Amyl Therapeutics (SRL) has been based in Liège since 2020, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.02m and equity of €3.55m; its revenue is not published. With 6.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 50.6%, below the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Amyl Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Bio-Sourcing Research and experimental development on natural sciences and engineering Liège · balance sheet €6.59m
- Bioxodes Research and experimental development on natural sciences and engineering Charleroi · balance sheet €7.68m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- ImmunXperts Research and experimental development on natural sciences and engineering Charleroi · balance sheet €9.58m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- Tanai Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.87m
- ExeVir Bio Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.76m
- Genflow Biosciences Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.74m
Frequently asked questions about Amyl Therapeutics
What is the revenue of Amyl Therapeutics?
Amyl Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Amyl Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0758775372 for Amyl Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0758.775.372.
Where is the registered office of Amyl Therapeutics?
According to the CBE register, the registered office of Amyl Therapeutics is in 4000 Liège.
What is the equity of Amyl Therapeutics?
At the close of the 2025 financial year, the equity of Amyl Therapeutics amounts to 3,547,141 €, a solvency of 50.6% of total assets.
How many people work at Amyl Therapeutics?
6.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Amyl Therapeutics?
The register lists 11 active mandates at Amyl Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Amyl Therapeutics within its sector?
By total assets for 2025, Amyl Therapeutics ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Amyl Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →